Trial Profile

The influence of CYP3A5 and ABCB1 genotype on the pharmacokinetics of Prograf and Advagraf.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tacrolimus (Primary)
Indications Renal transplant rejection
Focus Pharmacogenomic; Pharmacokinetics

Most Recent Events

09 May 2014 Accrual to date is 29% according to United Kingdom Clinical Research Network.
03 May 2014 Status changed from recruiting to active, no longer recruiting.
27 Mar 2014 According to UK Clinical Trials Register, status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com